Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:CRME
- CUSIP: N/A
- Web: www.cardiome.com
Capitalization:- Market Cap: $138.24 million
- Outstanding Shares: 31,927,000
Average Prices:- 50 Day Moving Avg: $3.44
- 200 Day Moving Avg: $3.04
- 52 Week Range: $2.35 - $5.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -39.36
- P/E Growth: -0.24
Sales & Book Value:- Annual Revenue: $23.37 million
- Price / Sales: 5.92
- Book Value: $0.88 per share
- Price / Book: 4.92
Profitability:- EBIDTA: ($15,620,000.00)
- Net Margins: -93.43%
- Return on Equity: -92.96%
- Return on Assets: -38.52%
Debt:- Debt-to-Equity Ratio: 0.48%
- Current Ratio: 4.65%
- Quick Ratio: 4.19%
Misc:- Average Volume: 94,852 shs.
- Beta: 1.07
- Short Ratio: 1.86
Frequently Asked Questions for Cardiome Pharma Corp (NASDAQ:CRME)
What is Cardiome Pharma Corp's stock symbol?
Cardiome Pharma Corp trades on the NASDAQ under the ticker symbol "CRME."
How were Cardiome Pharma Corp's earnings last quarter?
Cardiome Pharma Corp (NASDAQ:CRME) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.05. The firm had revenue of $5.19 million for the quarter, compared to analysts' expectations of $6.96 million. Cardiome Pharma Corp had a negative return on equity of 92.96% and a negative net margin of 93.43%. The business's revenue for the quarter was down 26.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.06) EPS. View Cardiome Pharma Corp's Earnings History.
Where is Cardiome Pharma Corp's stock going? Where will Cardiome Pharma Corp's stock price be in 2017?
5 equities research analysts have issued twelve-month price targets for Cardiome Pharma Corp's stock. Their forecasts range from $3.50 to $10.00. On average, they anticipate Cardiome Pharma Corp's stock price to reach $6.31 in the next year. View Analyst Ratings for Cardiome Pharma Corp.
Are investors shorting Cardiome Pharma Corp?
Cardiome Pharma Corp saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 103,857 shares, an increase of 32.2% from the April 13th total of 78,546 shares. Based on an average trading volume of 66,191 shares, the short-interest ratio is presently 1.6 days.
Who are some of Cardiome Pharma Corp's key competitors?
Who owns Cardiome Pharma Corp stock?
Cardiome Pharma Corp's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (15.34%), Clough Capital Partners L P (9.27%), Stonepine Capital Management LLC (8.64%), AlphaOne Investment Services LLC (1.73%), Sabby Management LLC (0.86%) and Renaissance Technologies LLC (0.79%). View Institutional Ownership Trends for Cardiome Pharma Corp.
Who sold Cardiome Pharma Corp stock? Who is selling Cardiome Pharma Corp stock?
Cardiome Pharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Westfield Capital Management Co. LP, Sabby Management LLC, Clough Capital Partners L P and AlphaOne Investment Services LLC. View Insider Buying and Selling for Cardiome Pharma Corp.
Who bought Cardiome Pharma Corp stock? Who is buying Cardiome Pharma Corp stock?
How do I buy Cardiome Pharma Corp stock?
Shares of Cardiome Pharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cardiome Pharma Corp stock cost?
One share of Cardiome Pharma Corp stock can currently be purchased for approximately $4.33.
Earnings History for Cardiome Pharma Corp (NASDAQ:CRME)Earnings History by Quarter for Cardiome Pharma Corp (NASDAQ:CRME)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/15/2017 | 3/31/2017 | ($0.15) | ($0.20) | $6.96 million | $5.19 million | View | N/A |  |
| 3/7/2017 | Q4 | ($0.16) | ($0.18) | $6.72 million | $7.00 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.20) | ($0.19) | $5.68 million | $5.20 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.19) | ($0.37) | $6.73 million | $5.90 million | View | N/A | |
| 5/13/2016 | Q116 | ($0.21) | ($0.06) | $6.34 million | $7.10 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.19) | ($0.37) | $7.74 million | $4.70 million | View | Listen | |
| 11/13/2015 | Q315 | ($0.23) | ($0.31) | $7.08 million | $5.00 million | View | Listen | |
| 8/5/2015 | Q215 | ($0.25) | ($0.43) | $7.67 million | $5.70 million | View | N/A | |
| 5/13/2015 | Q115 | ($0.28) | ($0.23) | $7.48 million | $5.50 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.14) | ($0.39) | $8.54 million | $7.00 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.13) | ($0.26) | $6.20 million | $7.81 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.16) | ($0.26) | $6.77 million | $7.67 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.11) | ($0.20) | $8.08 million | $7.60 million | View | N/A | |
| 3/27/2014 | | ($0.22) | ($0.53) | | | View | N/A | |
| 11/6/2013 | Q3 13 | ($0.21) | ($0.29) | | | View | N/A | |
| 8/2/2013 | Q2 13 | ($0.19) | ($0.22) | | | View | N/A | |
| 5/13/2013 | Q113 | $1.48 | $1.47 | $1.60 million | | View | N/A | |
| 3/15/2013 | Q412 | ($0.05) | $0.13 | $0.84 million | | View | N/A | |
| 11/13/2012 | Q312 | ($0.11) | ($0.22) | | | View | N/A | |
| 11/4/2011 | | ($0.10) | ($0.12) | | | View | N/A | |
| 5/16/2011 | | ($0.11) | ($0.12) | | | View | N/A | |
| 3/10/2011 | | ($0.08) | ($0.12) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cardiome Pharma Corp (NASDAQ:CRME)2017 EPS Consensus Estimate: ($0.53)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.12) | ($0.09) | ($0.11) |
| Q2 2017 | 2 | ($0.16) | ($0.14) | ($0.15) |
| Q3 2017 | 2 | ($0.13) | ($0.11) | ($0.12) |
| Q4 2017 | 2 | ($0.17) | ($0.14) | ($0.16) |
(Data provided by Zacks Investment Research)
Dividend History for Cardiome Pharma Corp (NASDAQ:CRME)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cardiome Pharma Corp (NASDAQ:CRME)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cardiome Pharma Corp (NASDAQ:CRME)
Latest Headlines for Cardiome Pharma Corp (NASDAQ:CRME)
| Source: |
|
Cardiome Pharma Corp (CRME) Chart for Saturday, May, 27, 2017
